New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:21 EDTPKI, DDXS, WAT, PACB, AFFX, SQNM, FLDMMaxim recommends life science tools, diagnostics ahead of earnings
Maxim expects 2014 to be a "great year" for life science tools and diagnostics stocks and recommends buying Affymetrix (AFFX), diaDexus (DDXS), Fluidigm (FLDM), Pacific Biosciences (PACB), PerkinElmer (PKI), Sequenom (SQNM) and Waters (WAT) ahead of the Q4 results. Maxim has a preference for Pacific Biosciences, PerkinElmer and Waters. The firm raised its price target for Fluidigm to $52 from $42 and for Pacific Biosciences to $9 from $8.
News For AFFX;DDXS;FLDM;PACB;PKI;SQNM;WAT From The Last 14 Days
Check below for free stories on AFFX;DDXS;FLDM;PACB;PKI;SQNM;WAT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
11:53 EDTPACBPacific Biosciences management to meet with Maxim
Subscribe for More Information
09:16 EDTPACBPacific Biosciences milestone payment shows Roche commitment, says Maxim
Maxim believes Roche's (RHHBY) milestone payment to Pacific Biosciences (PACB) indicates that the larger partner is committed to continuing the in vitro diagnostics program despite its recent acquisition and strategic investment with others. Maxim raised its 2014 revenue estimate for Pacific Biosciences to reflect the payment and recommends investors buy shares.
09:01 EDTPACBPacific Biosciences discloses achievement of development milestone
Subscribe for More Information
August 24, 2014
21:54 EDTSQNMPiper Jaffray to hold a bus tour
Subscribe for More Information
August 19, 2014
11:32 EDTPKI, SQNMLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use